Join the club for FREE to access the whole archive and other member benefits.

LMC provides background and success outlook on 14 leading senolytic companies


Key points from article :

Nathan Cheng looks at the companies mentioned in the recent Nature article on senescent cell therapies.

Unity Biotechnology

- repurposing small molecule cancer drugs

- only senolytics company to go public to date

Senolytic Therapeutics

- small molecule drug, nanoparticle delivery, monoclonal antibody (immunotherapy), prodrugs

- also pursuing senomorphic therapies

- daughter company of Life Biosciences

Rubedo Life Sciences

- small molecule drugs

- minimal details on their development timeline

Oisin Biotechnologies

- developing a novel flexible gene therapy platform

- gene delivery platform technology is cheap, flexible, and scalable

Cleara Biotech

- preclinical

- focussing on an improved version of FOXO4-DRI peptide


- joint venture company between Juvenescence and Antoxerene

- small molecule drugs that target the FOXO4-p53 interaction

Numeric Biotech

- focussing on neuroinflammatory and autoimmune diseases

Siwa Therapeutics

- monoclonal antibody that targets cells that have higher levels of glycolysis

- increase muscle mass in a naturally aged mouse model

Atropos Therapeutics

- FATES senescence suppressor / stimulator screening platform

Deciduous Therapeutics

- immune modulators

- still in stealth mode, no timeline on clinical trials

Dorian Therapeutics

- developing USP16-inhibitor senoblocker

- also improves cell viability in CAR-T cell therapy

Rejuversen -

- developing a monoclonal antibody targeting PD-L2 in order to recruit the immune system to clear senescent cells that promote cancer relapse or metastasis


- two-step therapy that first induces senescence in cancer cells followed by a senolytic to clear them


- modulating RNA splicing factors that become dysregulated with age

- lead indication is Idiopathic Pulmonary Fibrosis (IPF)

Comprehensive review of companies' clinical and financial state of play

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer.


Cleara is developing therapeutics to eliminate senescent cells.


Company developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.


Anti-aging company developing senoblockers.


Biotechnology company focused on development of treatments for age related diseases..


Drug development company focused on the senolytic technology to fight age-related diseases


Company that target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds.


Extending Health Span and Reverting Age-Related Diseases.


University of Exeter spinout aiming to develop senotherapeutic interventions


Pharmaceutical company that develops a novel class of medicines by targeting damaged cells.


Biotechnology company producing therapy that targets and destroys senescent cells.


Biotechnology company devoted to research of restoring human health